Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer
Phase of Trial: Phase I/II
Latest Information Update: 30 May 2017
At a glance
- Drugs Uprosertib (Primary) ; Dabrafenib; Trametinib
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 02 Nov 2016 Status changed from recruiting to suspended.
- 14 Oct 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.